M. Hallek, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, pp.5446-5456, 2008.

M. Hallek, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-2760, 2018.

E. Matutes, K. Owusu-ankomah, and R. Morilla, The immunological profile of B-Cell discorders and proposal of a scoring system for the diagnosis of CLL, 1994.

E. Matutes, J. Elisabeth, and M. Moreau, Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8 (CD79b), 1997.

F. P. Santos and S. O'brien, Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia: Are They the Same Disease?, The Cancer Journal, vol.18, pp.396-403, 2012.

A. C. Rawstron, Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia, N Engl J Med, vol.359, pp.575-583, 2008.

O. Landgren, B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia, N Engl J Med, vol.360, pp.659-667, 2009.

L. Guyader-peyrou and S. , Cancer incidence in France over the 1980-2012 period: Hematological malignancies. Revue d'Épidémiologie et de Santé Publique, vol.64, pp.103-112, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

T. Aurrant, SFH Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukemia (CLL), Hématologie, vol.19, pp.4-9, 2012.

S. Y. Kristinsson, Improved survival in chronic lymphocytic leukemia in the past decade: a populationbased study including 11,179 patients diagnosed between 1973-2003 in Sweden, Haematologica, vol.94, pp.1259-1265, 2009.

D. Catovsky, R. Wade, and M. Else, The clinical significance of patients' sex in chronic lymphocytic leukemia, Haematologica, vol.99, pp.1088-1094, 2014.

A. Monnereau, Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France, Int. J. Cancer, vol.132, pp.2378-2387, 2013.

N. Jacque and V. Leblond, La leucémie lymphoïde chronique : mise au point, La Presse Médicale, vol.48, pp.807-815, 2019.

M. R. Yuille, Familial chronic lymphocytic leukaemia: a survey and review of published studies, Br J Haematol, vol.109, pp.794-799, 2000.

L. R. Goldin, R. M. Pfeiffer, X. Li, and K. Hemminki, Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database, Blood, vol.104, pp.1850-1854, 2004.

J. R. Cerhan and S. L. Slager, Familial predisposition and genetic risk factors for lymphoma, Blood, vol.126, pp.2265-2273, 2015.

A. C. Rawstron, Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion, Blood, vol.100, pp.2289-2290, 2002.

J. L. Binet, A. Auquier, and G. Dighiero, A New Prognostic Classification of Chronic Lymphocytic Leukemia Derived from a Multivariate Survival Analysis, 1981.

P. Johansson, Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia, Leukemia Research, vol.34, pp.892-898, 2010.

J. M. Bennett, Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group, Journal of Clinical Pathology, vol.42, pp.567-584, 1989.

D. G. Oscier, Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12, British Journal of Haematology, vol.98, pp.934-939, 1997.

A. Criel, Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases, British Journal of Haematology, vol.97, pp.383-391, 1997.

D. Oscier, The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial, Br J Haematol, vol.174, pp.767-775, 2016.

A. C. Rawstron, Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project: ERIC/ESCCA Consensus: Reproducible CLL diagnosis by flow cytometry, Cytometry, vol.94, pp.121-128, 2018.

A. F. Sandes, CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry: CD200 Role in the Diagnosis of B-Cell Neoplasms, 2013.

T. Fukuda, Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a, Proceedings of the National Academy of Sciences 105, pp.3047-3052, 2008.

C. Visco, Autoimmune cytopenias in chronic lymphocytic leukemia: Autoimmune Cytopenias in CLL, Am. J. Hematol, vol.89, pp.1055-1062, 2014.

M. Tsang and S. A. Parikh, A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia, Curr Hematol Malig Rep, vol.12, pp.29-38, 2017.

R. B. Weiss, J. Freiman, S. L. Kweder, L. F. Diehl, and J. C. Byrd, Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia, JCO, vol.16, pp.1885-1889, 1998.

G. Reda, Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia, Am. J. Hematol, vol.87, pp.936-937, 2012.

F. Forconi and P. Moss, Perturbation of the normal immune system in patients with CLL, Blood, vol.126, pp.573-581, 2015.

T. J. Kipps, Chronic lymphocytic leukaemia, Nat Rev Dis Primers, vol.3, p.16096, 2017.

A. Randomized, Controlled Clinical Trial Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia*. Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic Leukemia, N Engl J Med, vol.319, pp.902-907, 1988.

F. Dhalla, Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?, J Clin Immunol, vol.34, pp.277-282, 2014.

D. Rossi, V. Spina, and G. Gaidano, Biology and treatment of Richter syndrome, Blood, vol.131, pp.2761-2772, 2018.

D. Rossi and G. Gaidano, Richter syndrome: pathogenesis and management, Seminars in Oncology, vol.43, pp.311-319, 2016.

E. J. Soilleux, Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review, Histopathology, vol.69, pp.1066-1076, 2016.

R. He, W. Ding, and D. Viswanatha, PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness, 2017.

Z. Mao, IgVH Mutational Status and Clonality Analysis of Richter?s Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution, The American Journal of Surgical Pathology, vol.31, pp.1605-1614, 2007.

W. Xiao, Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion, Human Pathology, vol.55, pp.108-116, 2016.

M. Hisada, Solid tumors after chronic lymphocytic leukemia, Blood, vol.98, 1979.

L. M. Morton, Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype, JCO, vol.28, pp.4935-4944, 2010.

L. Scarfò, A. J. Ferreri, and P. Ghia, Chronic lymphocytic leukaemia, Critical Reviews in Oncology/Hematology, vol.104, pp.169-182, 2016.

M. Hallek, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-2760, 2018.

H. Döhner, Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, N Engl J Med, vol.343, pp.1910-1916, 2000.

R. Ibbotson, Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant, Leukemia, vol.26, pp.170-172, 2012.

P. Baliakas, Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data: Translocations and karyotype complexity in CLL, Am. J. Hematol, vol.89, pp.249-255, 2014.

. For-the-european, Research Initiative on CLL (ERIC) et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations, Leukemia, vol.24, pp.2072-2079, 2010.

C. S. Tam, De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience, Blood, vol.114, pp.957-964, 2009.

J. Delgado, Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results: 17p-CLL, Br J Haematol, vol.157, pp.67-74, 2012.

T. Zenz, Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up, Blood, vol.112, pp.3322-3329, 2008.

T. Zenz, TP53 Mutation and Survival in Chronic Lymphocytic Leukemia, JCO, vol.28, pp.4473-4479, 2010.

D. Rossi, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, vol.123, pp.2139-2147, 2014.

M. Cavallari, Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia, Oncotarget, vol.9, 2018.

C. Haferlach, F. Dicker, S. Schnittger, W. Kern, and T. Haferlach, Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping, Leukemia, vol.21, pp.2442-2451, 2007.

P. Ouillette, Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks, Clinical Cancer Research, vol.16, pp.835-847, 2010.

J. Hamblin, J. Terry, and Z. Davis, Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia, 1999.

N. Damle and . Daniel-budman, & Klaus Dittmar. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia, 1999.

M. Trbusek, Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment, Leukemia, vol.20, pp.1159-1161, 2006.

A. Kröber and T. Seiler, V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia, 2002.

G. Tobin, Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia, Blood, vol.99, pp.2262-2264, 2002.

S. Deaglio, K. Mehta, and F. Malavasi, Human CD38: a (r)evolutionary story of enzymes and receptors, Leukemia Research, vol.25, pp.1-12, 2001.

S. Ibrahim, CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia, Blood, vol.98, pp.181-186, 2001.

M. Gentile, The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience, Br J Haematol, vol.130, pp.549-557, 2005.

M. Crespo, ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia, N Engl J Med, vol.348, pp.1764-1775, 2003.

P. Bulian, CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia, JCO, vol.32, pp.897-904, 2014.

E. M. Sagatys and L. Zhang, Clinical and Laboratory Prognostic Indicators in Chronic Lymphocytic Leukemia, Cancer Control, vol.19, pp.18-25, 2012.

M. Gentile, Predictive value of 2-microglobulin ( 2-m) levels in chronic lymphocytic leukemia since Binet A stages, Haematologica, vol.94, pp.887-888, 2009.

B. Simonsson, L. Wibell, K. Nilsson, and . ?2-microglobulin, Chronic Lymphocytic Leukaemia. Scandinavian Journal of Haematology, vol.24, pp.174-180, 2009.

J. Delgado, Beta 2 -microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate, British Journal of Haematology, vol.145, pp.801-805, 2009.

, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a metaanalysis of individual patient data, The Lancet Oncology, vol.17, pp.779-790, 2016.

P. H. Ellims, T. E. Gan, and M. B. Van-der-weyden, Thymidine kinase isoenzymes in chronic lymphocytic leukaemia, Br J Haematol, vol.49, pp.479-481, 1981.

C. Magnac, Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL, Leukemia, vol.17, pp.133-137, 2003.

W. Xu, Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors, Int J Hematol, vol.90, pp.205-211, 2009.

E. Szánthó, Serum Thymidine Kinase Activity: Analytical Performance, Age-Related Reference Ranges and Validation in Chronic Lymphocytic Leukemia, PLoS ONE, vol.9, p.91647, 2014.

S. Molica, D. Levato, N. Cascavilla, L. Levato, and P. Musto, Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and ?2-microglobulin in B-cell chronic lymphocytic leukemia, European Journal of Haematology, vol.62, pp.117-122, 2009.

M. Sarfati, S. Chevret, and C. Chastang, Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia, 1996.

A. Grelier, M. L. Garff-tavernier, F. Nauwelaers, M. Sarfati, and H. Merle-beral, Soluble CD23 measurement by CBA: A convenient and reliable quantification method in Chronic Lymphocytic Leukemia, 2013.

S. Molica and A. Alberti, Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia, 1987.

E. Montserrat, J. Sanchez-bisono, N. Viñolas, and C. Rozman, Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance, Br J Haematol, vol.62, pp.567-575, 1986.

K. R. Rai, A. Sawitsky, and E. P. Cronkite, Clinical staging of chronic lymphocytic leukemia, 1975.

D. Rossi, Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia, Blood, vol.121, pp.1403-1412, 2013.

M. Gentile, Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients, Blood, vol.128, pp.2093-2095, 2016.

C. Da-cunha-bang, I. Christiansen, and C. U. Niemann, The CLL-IPI applied in a population-based cohort, Blood, vol.128, pp.2181-2183, 2016.

S. A. Parikh, Chronic lymphocytic leukemia treatment algorithm, Blood Cancer Journal, vol.8, p.93, 2018.

G. Dighiero, Chlorambucil in Indolent Chronic Lymphocytic Leukemia, N Engl J Med, vol.338, pp.1506-1514, 1998.

, Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials, Journal of the National Cancer Institute, vol.91, pp.861-868, 1999.

M. Extermann, J. Overcash, G. H. Lyman, J. Parr, and L. Balducci, Comorbidity and functional status are independent in older cancer patients, JCO, vol.16, pp.1582-1587, 1998.

N. D. Gay, E. Kozin, C. Okada, A. V. Danilov, and S. Spurgeon, Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.59, pp.2258-2260, 2018.

M. Hallek, Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment, Am J Hematol, vol.94, pp.1266-1287, 2019.

B. D. Cheson, Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia, JCO, vol.30, pp.2820-2822, 2012.

A. C. Rawstron, International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, Leukemia, vol.21, pp.956-964, 2007.

, A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study, on behalf of ERIC (European Research Initiative on CLL), vol.30, pp.929-936, 2016.

P. A. Thompson and W. G. Wierda, Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL, Blood, vol.127, pp.279-286, 2016.

I. Del-giudice, Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? Front, Oncol, vol.9, p.689, 2019.

. Eric), Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL, CLL, vol.27, pp.142-149, 2013.

M. Gauthier, T. Comont, F. Vergez, and L. Ysebaert, Maladie résiduelle minime dans la leucémie lymphoïde chronique : un enjeu restant d'actualité, Bulletin du Cancer, vol.105, pp.1042-1051, 2018.

C. German and . Group, Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis, Leukemia, vol.23, pp.2007-2017, 2009.

S. Raponi, Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR, Br J Haematol, vol.166, pp.360-368, 2014.

A. C. Logan, High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment, Proceedings of the National Academy of Sciences, vol.108, pp.21194-21199, 2011.

M. Fürstenau, N. De-silva, B. Eichhorst, and M. Hallek, Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine, HemaSphere, vol.3, p.287, 2019.

M. Kwok, Minimal residual disease is an independent predictor for 10-year survival in CLL, Blood, vol.128, pp.2770-2773, 2016.

G. Kovacs, Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group, JCO, vol.34, pp.3758-3765, 2016.

P. Strati, Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL, Blood, vol.123, pp.3727-3732, 2014.

I. Krämer, Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial, Blood, vol.130, pp.1477-1480, 2017.

P. Dreger, TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial, Blood, vol.121, pp.3284-3288, 2013.

I. F. Khouri, Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome, Cancer, vol.117, pp.4679-4688, 2011.

J. Schetelig, Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group, JCO, vol.21, pp.2747-2753, 2003.

M. L. Sorror, Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning, JCO, vol.26, pp.4912-4920, 2008.

M. Michallet, Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: Long-term prospective multicenter study, Experimental Hematology, vol.41, pp.127-133, 2013.

, on behalf of the Chronic Leukemia Working Party of the EBMT et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus, Leukemia, vol.21, pp.12-17, 2007.

P. Dreger, Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?, Blood, vol.124, pp.3841-3849, 2014.

C. S. Link, Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation, Bone Marrow Transplant, vol.51, pp.793-798, 2016.

J. A. Dubovsky, Ibrutinib treatment ameliorates murine chronic graft-versus-host disease, J. Clin. Invest, vol.124, pp.4867-4876, 2014.

F. Nguyen-khac, C. Borie, E. Callet-bauchu, V. Eclache, and S. Struski, Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Annales de biologie clinique, vol.74, pp.561-567, 2016.

M. and J. R. , Functions and epigenetic aspects of miR-15/16: Possible future cancer therapeutics, Gene Reports, vol.12, pp.149-164, 2018.

A. Cimmino, miR-15 and miR-16 induce apoptosis by targeting BCL2, Proceedings of the National Academy of Sciences, vol.102, pp.13944-13949, 2005.

G. A. Calin, Nonlinear partial differential equations and applications: Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proceedings of the National Academy of Sciences, vol.99, pp.15524-15529, 2002.

U. Klein, The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia, Cancer Cell, vol.17, pp.28-40, 2010.

S. Stilgenbauer, Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders, Proceedings of the National Academy of Sciences, vol.93, pp.11837-11841, 1996.

T. Stankovic, Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia, The Lancet, vol.353, pp.26-29, 1999.

C. Kalla, Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B, European Journal of Cancer, vol.43, pp.1328-1335, 2007.

M. J. Rose-zerilli, ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial, Haematologica, vol.99, pp.736-742, 2014.

J. Dierlamm, Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications, Cancer Genetics and Cytogenetics, vol.94, pp.27-35, 1997.

P. A. Muller and K. H. Vousden, Mutant p53 in Cancer: New Functions and Therapeutic Opportunities, Cancer Cell, vol.25, pp.304-317, 2014.

X. S. Puente, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.475, pp.101-105, 2011.

L. Wang, SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia, N Engl J Med, vol.365, pp.2497-2506, 2011.

F. Pozzo, NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation, Leukemia, vol.30, pp.182-189, 2016.

V. Quesada, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat Genet, vol.44, pp.47-52, 2012.

A. D'avola, Global and MYC-Specific Translation Is Enhanced in Activated Chronic Lymphocytic Leukemia Cells Carrying NOTCH1 C.7541_7542delct Mutations, Blood, vol.128, pp.970-970, 2016.

V. Ljungström, Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations, Blood, vol.127, pp.1007-1016, 2016.

X. S. Puente, Non-coding recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.526, pp.519-524, 2015.

L. Wang, Somatic mutation as a mechanism of Wnt/?-catenin pathway activation in CLL, Blood, vol.124, pp.1089-1098, 2014.

C. I. Amaya-chanaga and L. Z. Rassenti, Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers, Best Practice & Research Clinical Haematology, vol.29, pp.79-89, 2016.

D. Rossi and G. Gaidano, The clinical implications of gene mutations in chronic lymphocytic leukaemia, Br J Cancer, vol.114, pp.849-854, 2016.

L. Mansouri, J. A. Wierzbinska, C. Plass, and R. Rosenquist, Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact, Seminars in Cancer Biology, vol.51, pp.1-11, 2018.

C. C. Oakes, DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia, Nat Genet, vol.48, pp.253-264, 2016.

D. A. Landau, Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia, Cancer Cell, vol.26, pp.813-825, 2014.

C. C. Oakes, Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia, Cancer Discovery, vol.4, pp.348-361, 2014.

S. Bhoi, Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2, Epigenetics, vol.11, pp.449-455, 2016.

N. Papakonstantinou, The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia, Oncotarget, vol.7, 2016.

G. A. Calin, A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia, N Engl J Med, vol.353, pp.1793-1801, 2005.

V. Balatti, TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia, Proc Natl Acad Sci, vol.112, pp.2169-2174, 2015.

R. Bichi, Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression, Proceedings of the National Academy of Sciences, vol.99, pp.6955-6960, 2002.

B. Cui, MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia, Blood, vol.124, pp.546-554, 2014.

F. Melchers, Checkpoints that control B cell development, J. Clin. Invest, vol.125, pp.2203-2210, 2015.

R. C. Rickert, New insights into pre-BCR and BCR signalling with relevance to B cell malignancies, Nat Rev Immunol, vol.13, pp.578-591, 2013.

A. V. Danilov, Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future, Clinical Therapeutics, vol.35, pp.1258-1270, 2013.

E. Ten-hacken and J. A. Burger, Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment, Biochimica et Biophysica Acta (BBA) -Molecular Cell Research, vol.1863, pp.401-413, 2016.

N. E. Harwood and F. D. Batista, The Cytoskeleton Coordinates the Early Events of B-cell Activation, Cold Spring Harbor Perspectives in Biology, vol.3, pp.2360-002360, 2011.

G. Packham, The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy, Haematologica, vol.99, pp.1138-1148, 2014.

Y. Herishanu, The lymph node microenvironment promotes B-cell receptor signaling, NF-?B activation, and tumor proliferation in chronic lymphocytic leukemia, Blood, vol.117, pp.563-574, 2011.

A. Quinquenel and F. Cymbalista, Signalisation du BCR et rôle du microenvironnement dans la leucémie lymphoïde chronique, 2014.

P. Deglesne, Survival Response to B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia Cells Irrespective of Zap70 Expression, Cancer Res, vol.66, pp.7158-7166, 2006.
URL : https://hal.archives-ouvertes.fr/hal-02060842

L. Roy and C. , The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia, Blood, vol.120, pp.356-365, 2012.

J. A. Burger and J. G. Gribben, The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies, Seminars in Cancer Biology, vol.24, pp.71-81, 2014.

A. Vlad, Down-regulation of CXCR4 and CD62L in Chronic Lymphocytic Leukemia Cells Is Triggered by B-Cell Receptor Ligation and Associated with Progressive Disease, Cancer Research, vol.69, pp.6387-6395, 2009.

V. Griggio, HIF-1? is over-expressed in leukemic cells from TP53 -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia, Haematologica, vol.105, pp.1042-1054, 2020.

M. Seiffert, HIF-1?: a potential treatment target in chronic lymphocytic leukemia, Haematologica, vol.105, pp.856-858, 2020.

S. Yokobori, Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies, 2014.

C. Billard, Apoptosis inducers in chronic lymphocytic leukemia, Oncotarget, vol.5, 2014.

L. Scarfò and P. Ghia, Reprogramming cell death: BCL2 family inhibition in hematological malignancies, Immunology Letters, vol.155, pp.36-39, 2013.

S. Faderl, Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL), Leukemia, vol.16, pp.1045-1052, 2002.

G. Packham and F. K. Stevenson, Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia, Immunology, vol.114, pp.441-449, 2005.

M. Hanada and D. Delia, bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia, 1993.

M. I. Del-principe, Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia, Haematologica, vol.101, pp.77-85, 2016.

R. Collado, Early ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis, Cancer Letters, vol.317, pp.144-149, 2012.

E. Vlashi and F. Pajonk, Cancer stem cells, cancer cell plasticity and radiation therapy, Seminars in Cancer Biology, vol.31, pp.28-35, 2015.

M. Leporrier, Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients, Blood, vol.98, pp.2319-2325, 2001.

W. U. Knauf, Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia, JCO, vol.27, pp.4378-4384, 2009.

N. Niederle, Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia, Ann Hematol, vol.92, pp.653-660, 2013.

B. Bellosillo, N. Villamor, and D. Colomer, In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia, 1999.

M. Hallek, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, The Lancet, vol.376, pp.1164-1174, 2010.

K. Fischer, Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, vol.127, pp.208-215, 2016.

B. Eichhorst, First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial, The Lancet Oncology, vol.17, pp.928-942, 2016.

J. L. Teeling, The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20, J Immunol, vol.177, pp.362-371, 2006.

W. G. Wierda, Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia, JCO, vol.28, pp.1749-1755, 2010.

P. Hillmen, Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial, The Lancet, vol.385, pp.1873-1883, 2015.

F. Offner, Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991, 2014.

S. M. Jaglowski, Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study, Blood, vol.126, pp.842-850, 2015.

E. Mössner, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, vol.115, pp.4393-4402, 2010.

V. Goede, Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions, N Engl J Med, vol.370, pp.1101-1110, 2014.

A. M. Frustaci, Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data, Therapeutic Advances in Hematology, vol.7, pp.222-230, 2016.

M. Le-garff-tavernier, J. Decocq, and C. De-romeuf, Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies, 2010.

A. Sawas, A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab, Br J Haematol, vol.177, pp.243-253, 2017.

M. Lunning, Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia, Blood, vol.134, pp.1811-1820, 2019.

J. P. Sharman, Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial, Br J Haematol, vol.176, pp.412-420, 2017.

G. Lozanski, Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions, Blood, vol.103, pp.3278-3281, 2004.

P. Hillmen, Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia, JCO, vol.25, pp.5616-5623, 2007.

S. Lepretre, Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial, Blood, vol.119, pp.5104-5110, 2012.

R. J. Kreitman, Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies, JCO, vol.23, pp.6719-6729, 2005.

R. J. Kreitman and I. Pastan, Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox, vol.17, pp.6398-6405, 2011.

J. C. Byrd, Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results, Blood, vol.108, pp.32-32, 2006.

E. Hertlein, Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells, Blood, vol.116, pp.2554-2558, 2010.

T. Robak, Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia, Br J Haematol, vol.176, pp.618-628, 2017.

S. Betrian, Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment, Blood Cancer Journal, vol.6, pp.496-496, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02348641

M. Z. Farooqui, Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial, The Lancet Oncology, vol.16, pp.169-176, 2015.

J. C. Byrd, Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.369, pp.32-42, 2013.

J. A. Burger, Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, N Engl J Med, vol.373, pp.2425-2437, 2015.

C. Moreno, Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial, The Lancet Oncology, vol.20, pp.43-56, 2019.

J. C. Byrd, Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, N Engl J Med, vol.371, pp.213-223, 2014.

A. Chanan-khan, Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study, The Lancet Oncology, vol.17, pp.200-211, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01885700

T. D. Shanafelt, Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia, N Engl J Med, vol.381, pp.432-443, 2019.

J. A. Burger, Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia, Blood, vol.133, pp.1011-1019, 2019.

J. A. Woyach, Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL, N Engl J Med, vol.379, pp.2517-2528, 2018.

J. A. Woyach, Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, N Engl J Med, vol.370, pp.2286-2294, 2014.

J. C. Byrd, Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.374, pp.323-332, 2016.

A. Liclican, Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on -and off -target inhibition, Biochimica et Biophysica Acta (BBA) -General Subjects, vol.1864, p.129531, 2020.

G. Salles, L. Karlin, and S. Rule, A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL), 2013.

A. V. Danilov, Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia, Clin Cancer Res clincanres, vol.3504, 2019.

J. C. Byrd, First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory Bcell NHL and CLL, Oncotarget, vol.9, 2018.

J. R. Brown, Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110?, for relapsed/refractory chronic lymphocytic leukemia, Blood, vol.123, pp.3390-3397, 2014.

R. R. Furman, Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.370, pp.997-1007, 2014.

A. D. Zelenetz, Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, doubleblind, placebo-controlled trial, The Lancet Oncology, vol.18, pp.297-311, 2017.

I. W. Flinn, The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL, Blood, vol.132, pp.2446-2455, 2018.

J. R. Brown, Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma, Clinical Cancer Research, vol.21, pp.3160-3169, 2015.

, Lunenburg Lymphoma Phase I/II Consortium et al. Final results of a phase 1b study of the safety and efficacy of the PI3K? inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies, Blood Cancer Journal, vol.8, p.16, 2018.

S. Assouline and L. Amrein, A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND, vol.216, 2017.

F. T. Awan, Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies, Br J Haematol, vol.175, pp.55-65, 2016.

T. Kadia, A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia, Blood, vol.118, pp.2858-2858, 2011.

P. C. Amrein, Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, Clinical Cancer Research, vol.17, pp.2977-2986, 2011.

J. W. Friedberg, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia, Blood, vol.115, pp.2578-2585, 2010.

F. T. Awan, Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study, Leukemia & Lymphoma, vol.60, pp.1972-1977, 2019.

A. Guo, Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment, Oncotarget, vol.8, 2017.

L. A. Andritsos, A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.60, pp.3461-3469, 2019.

M. K. Kashyap, Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway, Oncotarget, vol.7, 2016.

J. Hoellenriegel, The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization, Blood, vol.123, pp.1032-1039, 2014.

M. Steurer, Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia, Haematologica, vol.104, pp.2053-2060, 2019.

C. Cuesta-mateos, Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia, Cancer Immunol Immunother, vol.64, pp.665-676, 2015.

J. Melo-cardenas, M. Urquiza, T. J. Kipps, and J. E. Castro, Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression, Cancer Gene Ther, vol.19, pp.336-344, 2012.

R. R. Furman, A. Forero-torres, A. Shustov, and J. G. Drachman, A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.51, pp.228-235, 2010.

J. C. Byrd, Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.53, pp.2136-2142, 2012.

E. M. Mcwilliams, Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib, Blood Advances, vol.3, pp.447-460, 2019.

L. A. Vitale, Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia, Clinical Cancer Research, vol.18, pp.3812-3821, 2012.

R. R. French, Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation, Blood, vol.109, pp.4810-4815, 2007.

S. Ansell, A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors, j. immunotherapy cancer, vol.1, pp.2051-1426, 2013.

A. Yoda, I. Oishi, and Y. Minami, Expression and Function of the Ror-Family Receptor Tyrosine Kinases During Development: Lessons from Genetic Analyses of Nematodes, Mice, and Humans, Journal of Receptors and Signal Transduction, vol.23, pp.1-15, 2003.

H. E. Broome, L. Z. Rassenti, H. Wang, L. M. Meyer, and T. J. Kipps, ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia, Leukemia Research, vol.35, pp.1390-1394, 2011.

T. Fukuda, Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a, Proceedings of the National Academy of Sciences 105, pp.3047-3052, 2008.

B. Cui, High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia, Blood, vol.128, pp.2931-2940, 2016.

M. Y. Choi, Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia, Cell Stem Cell, vol.22, pp.951-959, 2018.

S. K. Bains, Mitochondria control of cell death induced by anti-HLA-DR antibodies, Leukemia, vol.17, pp.1357-1365, 2003.

T. S. Lin, A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia, Leukemia & Lymphoma, vol.50, pp.1958-1963, 2009.

K. Dunleavy, Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia, JCO, vol.23, pp.6607-6607, 2005.

C. Querfeld, Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, Cutaneous T Cell Lymphoma. Blood, vol.132, pp.2903-2903, 2018.

M. Nguyen, Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis, Proceedings of the National Academy of Sciences, vol.104, pp.19512-19517, 2007.

J. Joudeh and D. Claxton, Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms, Expert Opinion on Investigational Drugs, vol.21, pp.363-373, 2012.

T. J. Kipps, A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.56, pp.2826-2833, 2015.

A. W. Roberts, Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.374, pp.311-322, 2016.

S. Stilgenbauer, Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, The Lancet Oncology, vol.17, pp.768-778, 2016.

J. F. Seymour, Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia, N Engl J Med, vol.378, pp.1107-1120, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02348612

K. Fischer, Venetoclax and obinutuzumab in chronic lymphocytic leukemia, Blood, vol.129, pp.2702-2705, 2017.

K. Fischer, Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions, N Engl J Med, vol.380, pp.2225-2236, 2019.

P. Hillmen, Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study, JCO, vol.37, pp.2722-2729, 2019.

P. Casara, S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth, Oncotarget, vol.9, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01807731

A. W. Roberts, Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease, JCO, vol.30, pp.488-496, 2012.

T. J. Kipps, Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL), Blood, vol.118, pp.3904-3904, 2011.

T. J. Kipps, A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.56, pp.2826-2833, 2015.

J. R. Brown, Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.56, pp.3336-3342, 2015.

S. M. O'brien, Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia, Blood, vol.113, pp.299-305, 2009.

J. E. Castro, A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens, Blood, vol.110, pp.3119-3119, 2007.

R. Roskoski, Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs, Pharmacological Research, vol.107, pp.249-275, 2016.

M. Peyressatre, C. Prével, M. Pellerano, and M. Morris, Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors, Cancers, vol.7, pp.179-237, 2015.

A. Deep, Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review, New J. Chem, vol.42, pp.18500-18507, 2018.

J. Flynn, Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia, Leukemia, vol.29, pp.1524-1529, 2015.

C. Fabre, Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients, Cancer Chemother Pharmacol, vol.74, pp.1057-1064, 2014.

K. C. Goh, TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent antileukemic properties, Leukemia, vol.26, pp.236-243, 2012.

R. Chen, Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia, Blood, vol.113, pp.4637-4645, 2009.

J. S. Blachly, J. C. Byrd, and M. Grever, Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia, Seminars in Oncology, vol.43, pp.265-273, 2016.

T. S. Lin, Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease, JCO, vol.27, pp.6012-6018, 2009.

P. Ghia, Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia, Blood, vol.129, pp.1876-1878, 2017.

P. G. Longo, The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells, Blood, vol.111, pp.846-855, 2008.

J. Fecteau, Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1), Mol Med, vol.18, pp.19-28, 2012.

J. T. Larsen, Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study: A KT I NHIBITOR MK -2206 PLUS BR IN R ELAPSED CLL, Am J Hematol, vol.92, pp.759-763, 2017.

D. R. Friedman, Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL), Blood, vol.116, pp.1842-1842, 2010.

S. A. Hussain, Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity, Clinical Cancer Research, vol.13, pp.2144-2150, 2007.

S. O'brien, 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen, JCO, vol.27, pp.5208-5212, 2009.

B. Yu, Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia, Blood, vol.121, pp.136-147, 2013.

B. D. Cheson, Oblimersen for the treatment of patients with chronic lymphocytic leukemia, 2007.

D. Sampath, Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia, Blood, vol.119, pp.1162-1172, 2012.

S. Inoue, J. Riley, T. W. Gant, M. J. Dyer, and G. M. Cohen, Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa, Leukemia, vol.21, pp.1773-1782, 2007.

J. C. Byrd, A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia, Blood, vol.105, pp.959-967, 2004.

K. A. Blum, Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia, British Journal of Haematology, vol.147, pp.507-514, 2009.

V. Ribrag, Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study, Haematologica, vol.102, pp.903-909, 2017.

J. E. Amengual, Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib, Clin Cancer Res, vol.23, pp.3084-3096, 2017.

S. Frankland-searby and S. R. Bhaumik, The 26S proteasome complex: An attractive target for cancer therapy, Biochimica et Biophysica Acta (BBA) -Reviews on Cancer, vol.1825, pp.64-76, 2012.

D. A. Fennell, A. Chacko, and L. Mutti, BCL-2 family regulation by the 20S proteasome inhibitor bortezomib, Oncogene, vol.27, pp.1189-1197, 2008.

M. Baou, Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells, Haematologica, vol.95, pp.1510-1518, 2010.

S. Faderl, Phase II study of single-agent bortezomib for the treatment of patients with fludarabinerefractory B-cell chronic lymphocytic leukemia, Cancer, vol.107, pp.916-924, 2006.

S. V. Gupta, The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-B Response in Chronic Lymphocytic Leukemia Cells, Clinical Cancer Research, vol.19, pp.2406-2419, 2013.

Y. Zang, Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy, Clinical Cancer Research, vol.18, pp.5639-5649, 2012.

B. Lamothe, Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia, Blood, vol.125, pp.407-410, 2015.

F. T. Awan, Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma, Leukemia & Lymphoma, vol.56, pp.2834-2840, 2015.

A. Herriott, PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia, Oncotarget, vol.6, 2015.

V. J. Weston, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo, Blood, vol.116, pp.4578-4587, 2010.

G. Pratt, A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma, Br J Haematol, vol.182, pp.429-433, 2018.

C. Ciardullo, Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells, Haematologica, vol.104, pp.2429-2442, 2019.

J. E. Castro, ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia, Blood, vol.106, pp.2506-2512, 2005.

E. Bremer, G. Van-dam, B. J. Kroesen, L. De-leij, and W. Helfrich, Targeted induction of apoptosis for cancer therapy: current progress and prospects, Trends in Molecular Medicine, vol.12, pp.382-393, 2006.

T. Sher, Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics, Leukemia & Lymphoma, vol.51, pp.85-88, 2010.

L. A. Moutouh-de-parseval, L. Weiss, R. J. Delap, R. D. Knight, and J. Zeldis, Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia, JCO, vol.25, pp.5047-5047, 2007.

A. M. Fink, Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study, The Lancet Haematology, vol.4, pp.475-486, 2017.

X. C. Badoux, Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, JCO, vol.31, pp.584-591, 2013.

J. R. Brown, A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL, Leukemia, vol.24, pp.1972-1975, 2010.

W. Ding, Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL, Blood, vol.129, pp.3419-3427, 2017.

D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia, N Engl J Med, vol.365, pp.725-733, 2011.

C. J. Turtle, Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib, JCO, vol.35, pp.3010-3020, 2017.

S. Palmer, Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia, Br J Haematol, vol.141, pp.607-614, 2008.

C. Veuillen, Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy, J Clin Immunol, vol.32, pp.632-646, 2012.

L. Ruggeri and M. Capanni, Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation, 1999.

E. M. Mcwilliams, Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia, OncoImmunology, vol.5, p.1226720, 2016.

R. M. Gorczynski, CD200:CD200R-Mediated Regulation of Immunity, ISRN Immunology, vol.2012, pp.1-18, 2012.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, pp.252-264, 2012.

D. Mahadevan, Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint, CD200. j. immunotherapy cancer, vol.7, p.227, 2019.

R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000.

S. H. Lim, Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy, Blood, vol.118, pp.2530-2540, 2011.

A. Ljungars, A platform for phenotypic discovery of therapeutic antibodies and targets applied on, Chronic Lymphocytic Leukemia. npj Precision Onc, vol.2, p.18, 2018.

D. E. Spaner and A. Masellis, Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia, Leukemia, vol.21, pp.53-60, 2007.

C. S. Zent, Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.53, pp.211-217, 2012.

X. Liang, Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells, Blood, vol.115, pp.5041-5052, 2010.

D. E. Spaner, A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia, Leukemia, vol.24, pp.222-226, 2010.

J. Tomic, Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity, J Immunol, vol.176, pp.3830-3839, 2006.

D. Ziech, R. Franco, A. Pappa, and M. I. Panayiotidis, Reactive Oxygen Species (ROS)--Induced genetic and epigenetic alterations in human carcinogenesis, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.711, pp.167-173, 2011.

G. S. Devi, Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias, Clinica Chimica Acta, vol.293, pp.53-62, 2000.

H. Pelicano, D. Carney, and P. Huang, ROS stress in cancer cells and therapeutic implications, Drug Resistance Updates, vol.7, pp.97-110, 2004.

A. M. Oltra, F. Carbonell, C. Tormos, A. Iradi, and G. T. Sáez, Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic lerkenia, Free Radical Biology and Medicine, vol.30, pp.1286-1292, 2001.

G. Achanta, Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol ?, EMBO J, vol.24, pp.3482-3492, 2005.

A. A. Sablina, The antioxidant function of the p53 tumor suppressor, Nat Med, vol.11, pp.1306-1313, 2005.

D. Trachootham, Effective elimination of fludarabine-resistant CLL cells by PEITC through a redoxmediated mechanism, Blood, vol.112, pp.1912-1922, 2008.

D. Trachootham, J. Alexandre, and P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nat Rev Drug Discov, vol.8, pp.579-591, 2009.

J. Liu, Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROSmediated mechanism, Oncotarget, vol.7, 2016.

W. S. Xu, R. B. Parmigiani, and P. A. Marks, Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.26, pp.5541-5552, 2007.

S. S. Dinavahi, C. G. Bazewicz, R. Gowda, and G. P. Robertson, Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics, Trends in Pharmacological Sciences, vol.40, pp.774-789, 2019.

J. S. Rodríguez-zavala, L. F. Calleja, R. Moreno-sánchez, and B. Yoval-sánchez, Role of Aldehyde Dehydrogenases in Physiopathological Processes, Chem. Res. Toxicol, vol.32, pp.405-420, 2019.

S. A. Marchitti, C. Brocker, D. Stagos, and V. Vasiliou, Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily, Expert Opinion on Drug Metabolism & Toxicology, vol.4, pp.697-720, 2008.

I. Ma and A. L. Allan, The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells, Stem Cell Rev and Rep, vol.7, pp.292-306, 2011.

J. S. Moreb, D. Mohuczy, B. Ostmark, and J. R. Zucali, RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide, Cancer Chemother Pharmacol, vol.59, pp.137-137, 2006.

C. G. Bazewicz, S. S. Dinavahi, T. D. Schell, and G. P. Robertson, Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer, Immunology, vol.156, pp.47-55, 2019.

A. Terenzi, C. Pirker, B. K. Keppler, and W. Berger, Anticancer metal drugs and immunogenic cell death, Journal of Inorganic Biochemistry, vol.165, pp.71-79, 2016.

V. Koppaka, Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application, Pharmacol Rev, vol.64, pp.520-539, 2012.

G. Quash, Aldehyde dehydrogenase inhibitors: ?,?-Acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture, European Journal of Medicinal Chemistry, vol.43, pp.906-916, 2008.

G. Venton, Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors, Blood Cancer Journal, vol.6, pp.469-469, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02324893

R. A. Canuto, The effect of a novel irreversible inhibitor of aldehyde dehydrogenases 1 and 3 on tumour cell growth and death, Chemico-Biological Interactions, vol.130, pp.209-218, 2001.